These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 26096377)

  • 1. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
    Xiao AJ; Miller BW; Huntington JA; Nicolau DP
    J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ; Huntington JA; Long J; Caro L
    Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
    Zhang Z; Patel YT; Fiedler-Kelly J; Feng HP; Bruno CJ; Gao W
    J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
    Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
    J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
    Chandorkar G; Xiao A; Mouksassi MS; Hershberger E; Krishna G
    J Clin Pharmacol; 2015 Feb; 55(2):230-9. PubMed ID: 25196976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
    J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.
    Motos A; Kuti JL; Li Bassi G; Torres A; Nicolau DP
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
    Monogue ML; Stainton SM; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
    Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
    J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease.
    Xiao AJ; Caro L; Popejoy MW; Huntington JA; Kullar R
    Infect Dis Ther; 2017 Mar; 6(1):137-148. PubMed ID: 28013453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
    Melchers MJ; Mavridou E; Seyedmousavi S; van Mil AC; Lagarde C; Mouton JW
    Antimicrob Agents Chemother; 2015; 59(6):3373-6. PubMed ID: 25824214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.